Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992755 · ClinicalTrials.gov registry record · Phase 3
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
A Phase 3 study of Primary Pulmonary Hypertension, sponsored by Liquidia Technologies.
- Active
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT03992755: Active Phase 3 study of Primary Pulmonary Hypertension, sponsored by Liquidia Technologies.
NCT03992755 is a Phase 3 study of Primary Pulmonary Hypertension that is active but no longer recruiting, run by Liquidia Technologies. The registered enrollment target is 92 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03992755, a Phase 3 study of Primary Pulmonary Hypertension, is active but no longer recruiting, sponsored by Liquidia Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Primary Outcome
Treatment-emergent adverse events and serious adverse events will be grouped by MedDRA System Organ Class, dose level at onset, time on drug at onset, and relationship to dose titration.
Conditions Studied
Interventions
- DRUG LIQ861 Inhaled Treprostinil
Study Locations (20)
California
- West Los Angeles VA Healthcare Center - Los Angeles
- UC Davis Medical Center - Sacramento
- Los Angeles Biomedical Research Center - Torrance
Florida
- University of Florida - Gainesville
- Mayo Clinic-Jacksonville - Jacksonville
- AdventHealth - Orlando
Arizona
- Banner University Medical Center - Phoenix
- Arizona Pulmonary Specialists, Ltd. - Phoenix
Illinois
- Northwestern Medicine, Feinberg School of Medicine - Chicago
- University of Chicago Medicine - Chicago
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Emory University School of Medicine - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Ochsner Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 3 |
What the registry record for NCT03992755 still lists
NCT03992755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Primary Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which LIQ861 Inhaled Treprostinil is the first listed.
NCT03992755 names 20 study sites across 14 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03992755 about?
NCT03992755 is a clinical study titled "Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil". The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT03992755?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2019-07-18. Estimated completion is 2025-05-31.
What conditions does trial NCT03992755 study?
This clinical trial studies the following conditions: Primary Pulmonary Hypertension.
What interventions are being tested in trial NCT03992755?
The interventions under investigation include: LIQ861 Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT03992755?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992755 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03992755's enrollment target sits among peer trials
92 1723rd of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI